| Autor: |
Ashaye, Ajibade O, Khankhel, Zarmina, Xu, Yingxin, Fahrbach, Kyle, Mokgokong, Ruth, Orme, Michelle E, Lang, Kathryn, Cappelleri, Joseph C, Mamolo, Carla |
| Zdroj: |
Future Oncology; Feb2019, Vol. 15 Issue 6, p663-681, 19p |
| Abstrakt: |
Aim: To evaluate the comparative efficacy and safety of gemtuzumab ozogamicin + daunorubicin-cytarabine (GO + DA) versus common induction therapies for newly diagnosed acute myeloid leukemia. Materials & methods: A network meta-analysis following a systematic literature review. Results: In base-case analyses, GO + DA was associated with significantly greater overall survival and relapse-free survival versus most comparators, and similar rates of complete remission versus all evaluated comparators. Similar findings were seen in the subgroup analyses. Grade 3+ bleeding and hepatic events were higher with GO + DA versus some comparators, consistent with GO's profile. No differences were found for other evaluated outcomes. Conclusion: GO + DA provides significant overall survival and relapse-free survival benefit versus evaluated induction regimens for newly diagnosed acute myeloid leukemia. To evaluate the efficacy and safety of gemtuzumab ozogamicin + daunorubicin-cytarabine (GO + DA) compared with common treatments for patients newly diagnosed with acute myeloid leukemia, we systematically reviewed the literature published on the topic, then performed a network meta-analysis. In our base-case analyses, GO + DA was associated with significantly greater overall survival and relapse-free survival versus most comparative treatments, and with similar rates of complete remission versus all evaluated comparators. Grade 3+ bleeding and liver events were higher with GO + DA than with some comparators. These findings are consistent with what is known about the efficacy and safety profile of GO. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
